Response Genetics, Inc. (NASDAQ:RGDX), a company focused on the development and commercialization of molecular diagnostic tests for cancer, announced today the addition of Christine Meda as the Company’s president. Kathleen Danenberg, who held this position previously, will continue to act as chief executive officer of the Company. In her role, Ms. Meda will be responsible for helping in the execution of the Company’s strategy and operations on a day-to-day basis and, with her unique expertise in cancer diagnostics, leading the Company in new areas of the market, such as the development of companion diagnostics.
“With her strong background in the diagnostics industry, Christine’s strategic vision and considerable business experience have helped companies successfully develop, launch and market products,” said Ms. Danenberg, CEO. “And with our current growth rate in the double digits, her addition to the senior management team will help Response Genetics expand its market and realize its growth potential.”
Ms. Meda brings nearly 30 years of experience in strategic partnering, operations and marketing to her role at Response Genetics. Most recently, Ms. Meda was president and chief executive officer of Arcxis Biotechnologies, an early-stage molecular diagnostics company. Ms. Meda also founded and is president of RxDxLink, a consulting service company to early state and small biotechnology companies. She served as president and chief operating officer for Diamics, Inc., an early-stage cancer diagnostics company, and over a four year period before that, she held various positions of increasing importance at Roche Molecular Diagnostics, including vice president of Business Development and vice president of Women’s Health, where she had portfolio responsibility bringing five molecular diagnostics through the pipeline to market. Ms. Meda received a Bachelor of Science degree in the State University of New York at Potsdam.
Ms. Meda, commenting on her appointment said, “I am pleased to be joining Response Genetics, a company with a unique platform technology and differentiated product offering. I look forward to applying my skills and experience knowing that I am not only providing value to the company and its shareholders, but helping improve the diagnostic information used to treat people with cancer.”